RPT has gained considerable momentum in recent years, with a series of pivotal trials (e.g., VISION (3), PSMAfore (9), TheraP (5), and SPLASH (10)) demonstrating the benefits of 177Lu-PSMA–based RPTs, including reduced risks for radiographic disease progression and death, against standards of care in patients with previously treated, advanced PC. This evidence concerns the gene FOLH1 and pachyonychia congenita.